Valuation: CStone Pharmaceuticals

Market Cap 7.6B 1.13B 969M 907M 829M 1.56B 108B 1.58B 10.73B 4.17B 54.38B 4.25B 4.15B 180B P/E 2026 *
-357x
P/E 2027 * 7.1x
Enterprise Value 7.08B 1.05B 902M 844M 771M 1.46B 101B 1.47B 9.98B 3.88B 50.6B 3.95B 3.87B 167B EV / Sales 2026 *
14.8x
EV / Sales 2027 * 2.33x
Free-Float
80.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: CStone Pharmaceuticals

1 day-19.32%
1 week-2.03%
Current month-3.41%
1 month-3.41%
3 months-32.10%
6 months-15.16%
Current year-23.20%
1 month 0.69
Extreme 0.6858
0.7
Current year 0.59
Extreme 0.5945
1.01
1 year 0.59
Extreme 0.5945
1.01
3 years 0.11
Extreme 0.1139
1.01
5 years 0.11
Extreme 0.1139
1.78
10 years 0
Extreme 0.0001
2.6
Manager TitleAgeSince
Chief Executive Officer 62 25/08/2022
Director of Finance/CFO - 18/01/2023
Chief Operating Officer 46 01/08/2016
Director TitleAgeSince
Chairman 55 -
Director/Board Member 62 25/08/2022
Director/Board Member 63 09/07/2021
Change 5-day change 1-year change 3-year change Capi.($)
-19.32%-2.03% - - 1.1B
-0.55%+2.88%+44.85%-0.25% 83.28B
-3.59%+116.99%+451.76%+24.16% 57.94B
+0.48%+23.89%-21.93%-35.75% 57.77B
+1.42%+1.61%-0.67%+34.08% 51.75B
-0.77%+2.14%+9.45%+170.00% 49.35B
+0.15%+3.76%+59.15%-17.31% 32.03B
+0.05%+3.55%+50.87%+99.10% 25.91B
-2.83%+6.08%+0.05%+223.58% 22.74B
-1.74%-1.27%+55.75%+107.91% 16.87B
Average -2.65%+20.75%+72.14%+67.28% 44.18B
Weighted average by Cap. -0.72%+25.31%+83.57%+46.23%

Financials

2026 *2027 *
Net sales 479M 71.29M 61.1M 57.16M 52.26M 98.61M 6.83B 99.66M 676M 263M 3.43B 268M 262M 11.34B 1.71B 255M 218M 204M 187M 352M 24.4B 356M 2.42B 940M 12.25B 957M 936M 40.54B
Net income -243M -36.17M -31M -29M -26.52M -50.04M -3.46B -50.57M -343M -133M -1.74B -136M -133M -5.75B 687M 102M 87.63M 81.98M 74.95M 141M 9.79B 143M 970M 377M 4.92B 384M 376M 16.27B
Net Debt -528M -78.57M -67.33M -62.99M -57.59M -109M -7.52B -110M -745M -290M -3.78B -295M -289M -12.5B -3.6B -536M -459M -430M -393M -741M -51.32B -749M -5.08B -1.98B -25.77B -2.01B -1.97B -85.26B
Logo CStone Pharmaceuticals
CStone Pharmaceuticals is an investment holding company primarily engaged in research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Employees
136
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.761CNY
Average target price
12.33CNY
Spread / Average Target
+158.99%

Quarterly revenue - Rate of surprise